SBC Medical Group (NASDAQ:SBC) Given Sell (D+) Rating at Weiss Ratings

Key Points

• SBC Medical Group's stock received a "sell (D+)" rating from Weiss Ratings, reinforcing a negative sentiment on its performance.
• Despite the downgrade, Wall Street Zen upgraded the stock from a "hold" rating to a "buy" rating" just days earlier, indicating mixed opinions among analysts.
• The company reported a net loss of $0.12 EPS in its latest earnings report, falling short of analyst expectations, with revenue also below anticipated figures.

SBC Medical Group (NASDAQ:SBC - Get Free Report)'s stock had its "sell (d+)" rating reaffirmed by stock analysts at Weiss Ratings in a research report issued on Tuesday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of SBC Medical Group from a "hold" rating to a "buy" rating in a report on Saturday, September 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of "Sell".

SBC Medical Group Price Performance

NASDAQ SBC traded up $0.10 on Tuesday, reaching $4.25. 42,640 shares of the company's stock traded hands, compared to its average volume of 65,673. The stock has a market cap of $440.97 million, a PE ratio of 13.27 and a beta of 1.29. The stock has a 50-day simple moving average of $4.29 and a 200 day simple moving average of $4.22. SBC Medical Group has a 12 month low of $2.62 and a 12 month high of $8.20. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.98 and a quick ratio of 3.95.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.12). The business had revenue of $43.36 million during the quarter, compared to analysts' expectations of $44.71 million. SBC Medical Group had a return on equity of 20.76% and a net margin of 17.71%. As a group, research analysts predict that SBC Medical Group will post 5.02 earnings per share for the current year.

Institutional Investors Weigh In On SBC Medical Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SBC. Geode Capital Management LLC purchased a new stake in SBC Medical Group in the second quarter worth $455,000. SBI Securities Co. Ltd. lifted its holdings in shares of SBC Medical Group by 227.3% during the second quarter. SBI Securities Co. Ltd. now owns 54,177 shares of the company's stock valued at $251,000 after purchasing an additional 37,623 shares during the last quarter. New York State Common Retirement Fund purchased a new position in shares of SBC Medical Group during the second quarter valued at approximately $104,000. Finally, XTX Topco Ltd purchased a new position in shares of SBC Medical Group during the second quarter valued at approximately $64,000. 60.82% of the stock is owned by hedge funds and other institutional investors.

About SBC Medical Group

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.